Verici Dx is gaining traction with Tutivia, its kidney transplant blood test, as more US transplant centres use the product and existing centres continue to reorder.
Testing volumes are rising, repeat use is improving, and the company is showing early evidence that its commercial model can scale in a focused medical niche.
Tutivia volumes increased 34% quarter on quarter in the first quarter of 2026. Diagnostic companies need evidence that hospitals and clinicians will keep using the test in real-world workflows. Repeat centre activity is particularly relevant. When transplant centres come back after initial use, it suggests the test may be becoming part of ongoing patient management rather than remaining a one-off trial.
Verici Dx is targeting a clearly defined market where timing and clinical confidence are important. Kidney transplant patients face the ongoing risk of rejection, and clinicians need tools that can help assess risk without relying only on invasive procedures. Tutivia is positioned to support earlier decision-making after transplant, which gives the company a focused commercial message.
Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.
